Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Similar Goals, Divergent Paths: Exploring Approaches to Hepatitis C Treatment Protocols in Heart Transplantation.

    Feb 1, 2025DOI: 10.1016/j.cardfail.2024.11.020Journal ArticleJCF

    Written by: Roopa A RaoSonu AbrahamAmanda R VestMrudula MunnagalaAnju BhardwajJohanas ContrerasIndranee RajapreyerShelley Hall

    Find these authors on Roon

    AB
    Dr. Anju Bhardwaj
    Advanced Heart Failure · UTHealth

    Summary

    BACKGROUND: Heart transplantation from hepatitis C-positive donors is on the rise, yet there exists divergence in approaches to managing recipients of these organs. Practices range from prophylactic treatment of recipients prior to transplantation to delayed treatment following the detection of viremia, with no established consensus on the optimal approach.METHODS: An online survey was conducted among the heart transplant centers in the United States and Canada from January 2023-February 2024. The survey gathered comprehensive information from the institutions regarding direct antiviral (DAA) therapies used, timing and duration of DAA, frequency of viral load testing, adverse effects, virological response, and immunosuppressive therapy modifications. The treatment pathways were categorized based on the timing of treatment initiation into prophylactic, preemptive or reactive approaches. Analysis was restricted to adult transplant programs in the U.S. that had an HCV transplant protocol and performed at least 1 HCV NAT-positive transplant. The Scientific Registry of Transplant Recipients database was queried for total heart transplants using hepatitis C virus nucleic acid testing (HCV NAT)-positive donors.RESULTS: Of 122 heart transplant programs, 35 (28.7%) institutions responded; 689 heart transplants (49.1%) using HCV NAT-positive donors were captured across institutions. Among 30 U.S. institutions performing adult heart transplantation with HCV NAT-positive donor hearts, 5 (16.7%) used prophylactic, 9 (30%) preemptive and 16 (53.3%) reactive treatment pathways. Most employed pan-genotype DAA therapies for a median of 12 weeks. Significant heterogeneity existed in treatment and monitoring protocols.CONCLUSION: Practice patterns for management of HCV NAT-positive donor hearts vary significantly. Establishing registries and randomized control trials for these patients is crucial for guiding future practices.
    ABDr. Anju Bhardwaj

    Dr. Anju Bhardwaj

    Cardiology · Advanced Heart Failure & Transplantation
    The University of Texas Health Science Center at Houston
    anju